IIFL Securities's Stock Pick Today: Buy Piramal Pharma with Target Rs 160

IIFL Securities has issued a buy recommendation for Piramal Pharma with a target price of Rs 160, representing a potential upside of approximately 4.5%. The current market price of Piramal Pharma stands at Rs 153.05. This recommendation is supported by the company's strong performance in the domestic formulations market, particularly in the gastrointestinal and respiratory segments. IIFL Securities anticipates that Piramal Pharma will continue to benefit from increasing demand for healthcare products and services in the coming quarters.

About Piramal Pharma:

Piramal Pharma Limited (PPL) is a global pharmaceutical company headquartered in Mumbai, India. It is a subsidiary of the Piramal Group, a diversified conglomerate with interests in healthcare, financial services, and real estate. PPL has a presence in over 100 countries and its products are used by millions of patients worldwide. The company's core business segments include branded generics, contract development and manufacturing (CDMO), and inhalation. PPL is committed to providing high-quality, affordable medicines to patients around the world.

52 Week Price Trend:

Piramal Pharma (PPLPHARMA), currently trading at Rs. 153.05, has had a remarkable year, rising by more than 149% from its 52-week low of Rs. 61.62. While it belum reached its 52-week high of Rs. 149, the company's steady growth and strong financial performance suggest that it has potential for further appreciation. Piramal Pharma's commitment to innovation, focus on niche therapies, and expanding global presence position it well for continued success in the pharmaceutical industry.

Stratzy's MOST Analysis:

PPLPHARMA has received a BB- rating from Stratzy's MOST framework, indicating a medium fundamental risk level. This rating is based on an assessment of the company's management, outlook, safety, and trend. Specifically, PPLPHARMA has received positive ratings in the areas of management and outlook, but lower ratings in safety and trend. Overall, the BB- rating suggests that PPLPHARMA is a company with solid fundamentals, but there are some areas where improvement could be made.

Fundamental and Technical information provided in this blog were last updated on 04 May, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.